Antegrade Autologous Blood Reinfusion After CPB

Recruiting now

Conditions studied: Coronary Artery Disease

In brief

This prospective observational study aims to evaluate the effect of antegrade pump blood reinfusion using the crystalloid "chase" technique on postoperative transfusion requirements in adult patients undergoing cardiac surgery with cardiopulmonary bypass. At the end of cardiopulmonary bypass, blood remaining within the cardiopulmonary bypass circuit is reinfused antegradely through the arterial line using a crystalloid chase, without collection or storage. Blood remaining within the bypass circuit after surgery represents a valuable source of autologous blood, and its reinfusion may contribute to perioperative blood conservation strategies. Patients receiving antegrade pump blood reinfusion via the chase technique will be compared with those managed without reinfusion, without any intervention by the investigators. The primary outcome is postoperative blood transfusion requirement.

Key facts

Study ID

NCT07420582

Run by

Kocaeli City Hospital

People needed

130

Starts

2026-02-23

Expected to finish

2026-06-15

Last updated by the study team

2026-02-24

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 to 80 years
• Patients undergoing elective, isolated coronary artery bypass grafting surgery using cardiopulmonary bypass (on-pump).

You may not qualify if…

• Emergency or Redo cardiac surgery
• Concomitant cardiac procedures (e.g., valve repair/replacement or aortic surgery).
• Planned or intraoperative conversion to off-pump coronary artery bypass grafting
• Preoperative hematocrit <30% or known inherited/acquired bleeding disorders.
• Preoperative left ventricular ejection fraction <30%.
• Thrombocytopenia (e.g., platelet count <100×10³/µL) or abnormal coagulation tests.
• Use of antiplatelet agents other than aspirin without appropriate discontinuation according to current guideline-recommended preoperative intervals.
• Use of anticoagulant therapy without appropriate preoperative discontinuation according to current guideline recommendations.
• Use of non-steroidal anti-inflammatory drugs (NSAIDs) without appropriate discontinuation prior to surgery.
• Severe renal dysfunction (eGFR <30 mL/min/1.73 m² or dialysis) and/or severe hepatic dysfunction (Child-Pugh B-C or coagulopathy).
• Active infection or systemic inflammatory/autoimmune disease.
• Active malignancy requiring ongoing treatment
• Refusal or inability to provide written informed consent.

Where it is running

• Kocaeli City Hospital — Kocaeli, Izmit, Turkey (Türkiye) (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.